Serum Cholesterol Levels at the Onset of Bloodstream Infection Have Prognostic Value


Objective: The aims of this study were to investigate the changes in serum cholesterol levels at the onset of bloodstream infection (BSI) and to determine whether serum cholesterol levels were associated with patients’ clinical backgrounds and the prognosis of BSI; Methods: A retrospective chart review was done to collect demographic information and the subjects’ medical history, invasive procedures, and medications; Patients and Methods: From April 2003 to March 2006, all patients aged ≥20 years with positive blood cultures in the University of Tokyo Hospital (a tertiary teaching hospital with 1200 beds) were enrolled; Results: Average cholesterol levels before the onset of BSI were 166.5 ± 46.5 mg/dL, and, at the onset of BSI, they decreased to 134.4 ± 45.0 mg/dL (p < 0.001). Thirty-day survivors had higher cholesterol levels both before and at the onset of BSI than non-survivors. Cholesterol levels at the onset of BSI were associated with the organisms of BSI. Patients with lower cholesterol levels tended to have higher 30-day mortality rates and longer medical treatment than patients with higher cholesterol levels (13% vs 3%, p = 0.12; 24.3 days vs 18.4 days, p = 0.15); Conclusion: Cholesterol levels at the onset of BSI could be used as a prognostic marker in patients with BSI.

Share and Cite:

T. Kitazawa, S. Yanagimoto, K. Tatsuno, A. Fukushima, S. Okugawa and Y. Ota, "Serum Cholesterol Levels at the Onset of Bloodstream Infection Have Prognostic Value," Advances in Infectious Diseases, Vol. 2 No. 4, 2012, pp. 100-105. doi: 10.4236/aid.2012.24017.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] R. S. Rosenson, “Myocardial Injury: The Acute Phase Response and Lipoprotein Metabolism,” Journal of the American College of Cardiology, Vol. 22, No. 3, 1993, pp. 933-940. Hdoi:10.1016/0735-1097(93)90213-K
[2] H. J. van Leeuwen, E. C. Heezius, G. M. Dallinga, J. A. van Strijp, J. Verhoef and K. P. van Kessel, “Lipoprotein Metabolism in Patients with Severe Sepsis,” Critical Care Medicine, Vol. 31, No. 5, 2003, pp. 1359-1366. Hdoi:10.1097/01.CCM.0000059724.08290.51
[3] P. Fraunberger, J. Hahn, E. Holler, A. K. Walli and D. Seidel, “Serum Cholesterol Levels in Neutropenic Patients with Fever,” Clinical Chemistry and Laboratory Medicine, Vol. 40, No. 3, 2002, pp. 304-307. Hdoi:10.1515/CCLM.2002.048
[4] B. R. Gordon, T. S. Parker, D. M. Levine, S. D. Saal, J. C. Wang, B. J. Sloan, P. S. Barie and A. L. Rubin, “Low Lipid Concentrations in Critical Illness: Implications for Preventing and Treating Endotoxemia,” Critical Care Medicine, Vol. 24, No. 4, 1996, pp. 584-589. Hdoi:10.1097/00003246-199604000-00006
[5] M. H. Tsai, Y. S. Peng, Y. C. Chen, J. M. Lien, Y. C. Tian, J. T. Fang, H. H. Weng, P. C. Chen, C. W. Yang and C. S. Wu, “Low Serum Concentration of Apolipoprotein A-I is an Indicator of Poor Prognosis in Cirrhotic Patients with Severe Sepsis,” Journal of Hepatology, Vol. 50, No. 5, 2009, pp. 906-915. Hdoi:10.1016/j.jhep.2008.12.024
[6] J. Y. Chien, J. S. Jerng, C. J. Yu and P. C. Yang, “Low Serum Level of High-Density Lipoprotein Cholesterol Is a Poor Prognostic Factor for Severe Sepsis,” Critical Care Medicine, Vol. 33, No. 8, 2005, pp. 1688-1693. Hdoi:10.1097/01.CCM.0000171183.79525.6B
[7] C. Chenaud, P. G. Merlani, O. Bandshapp and B. Ricou, “Serum Lipids or Apolipoprotein A-I and Disease Severity of Meningococcal Sepsis,” Critical Care Medicine, Vol. 34, No. 1, 2006, pp. 270-271. Hdoi:10.1097/01.CCM.0000191256.88821.28
[8] W. A. Knaus, E. A. Draper, D. P. Wagner and J. E. Zimmerman, “APACHE II: A Severity of Disease Classification System,” Critical Care Medicine, Vol. 13, No. 10, 1985, pp. 818-829. Hdoi:10.1097/00003246-198510000-00009
[9] D. M. Levine, T. S. Parker, T. M. Donnelly, A. Walsh and A. L. Rubin, “In vivo Protection against Endotoxin by Plasma High Density Lipoprotein,” Proceedings of the National Academy of Sciences (USA), Vol. 90, No. 24, 1993, pp. 12040-12044. Hdoi:10.1073/pnas.90.24.12040
[10] D. Pajkrt, P. G. Lerch, T. van der Poll, M. Levi, M. Illi, J. E. Doran, B. Arnet, A. van den Ende, J.W. ten Cate and S. J. van Deventer, “Differential Effects of Reconstituted High-Density Lipoprotein on Coagulation, Fibrinolysis and Platelet Activation during Human Endotoxemia,” Journal of Thrombosis and Haemostasis, Vol. 77, No. 2, 1997, pp. 303-307.
[11] P. Vyroubal, C. Chiarla, I. Giovannini, R. Hyspler, A. Ticha, D. Hrnciarikova and Z. Zadak, “Hypocholesterolemia in Clinically Serious Conditions—Review,” Biomedical Papers, Vol. 152, No. 2, 2008, pp. 181-189. Hdoi:10.5507/bp.2008.029
[12] C. Chiarla, I. Giovannini and J. H. Siegel, “The Relationship between Plasma Cholesterol, Amino Acids and Acute Phase Proteins in Sepsis,” Amino Acids, Vol. 27, No. 1, 2004, pp. 97-100. Hdoi:10.1007/s00726-004-0064-x
[13] J. Cohen and E. Abraham, “Microbiologic Findings and Correlations with Serum Tumor Necrosis Factor-Alpha in Patients with Severe Sepsis and Septic Shock,” International Journal of Infectious Diseases, Vol. 180, No. 1, 1999, pp. 116-121. Hdoi:10.1086/314839
[14] P. Kragsbjerg, H. Holmberg and T. Vikerfors, “Dynamics of Blood Cytokine Concentrations in Patients with Bacteremic Infections,” Scandinavian Journal of Infectious Diseases, Vol. 28, No. 4, 1996, pp. 391-398. Hdoi:10.3109/00365549609037926
[15] P. Fraunberger, G. Pilz, P. Cremer, K. Werdan and A. K. Walli, “Association of Serum Tumor Necrosis Factor Levels with Decrease of Cholesterol during Septic Shock,” Shock, Vol. 10, No. 5, 1998, pp. 359-363. Hdoi:10.1097/00024382-199811000-00009

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.